According to a recent study, concomitant ixekizumab and tirzepatide improved skin clearance and reductions in weight in patients with moderate-to-severe psoriasis.
Risankizumab linked to lower risk of serious infection than other systemic treatments
According to a recent study, risankizumab was associated with a lower risk of serious infections when compared to other systemic treatments for psoriasis.
Researchers review relative efficacy of immunomodulatory therapies for scalp PsO
Researchers recently reviewed the relative efficacy of 22 immunomodulatory treatments, including placebo, for the treatment of scalp psoriasis.
Researchers evaluate effectiveness of biologics on bio-naïve and bio-experienced PsO patients
In a recent study, researchers identify biologics for psoriasis that have better drug survival in bio-naïve or bio-experienced patients—a finding they hope can guide treatment choice in clinical practice.
Almost half of female PsO patients have experienced intimate partner violence
According to a recent study, 46.3% of female patients with psoriasis have been exposed to at least one type of intimate partner violence (IPV).
Mediterranean diet improves psoriasis severity, regardless of weight loss
According to a recent study, adults with mild-to-moderate psoriasis saw significant improvement in their disease severity while adopting a Mediterranean diet for a 16-week period alongside stable topical therapy.
Concomitant methotrexate adds no benefit to PsO treatment compared to adalimumab monotherapy
According to a recent study, treating psoriasis with adalimumab and concomitant methotrexate has no difference in effectiveness and persistence when compared to adalimumab monotherapy.
Patient QoL, disease burden for PsO may be similar whether high or low BSA
According to a recent study, psoriasis patients with low body surface area (BSA) involvement may experience similar quality of life (QoL) and disease burden as patients with high BSA.
Guselkumab effective in scalp PsO across all skin tones
According to a recent study, guselkumab is effective in treating moderate-to-severe scalp psoriasis in patients with Fitzpatrick Skin Types IV through VI.
GPP patients have five times higher mortality risk than those without
According to a recent study, patients with generalized pustular psoriasis (GPP) have a five times higher risk of all-cause mortality at one year than those without GPP.
HealthMinute.TV 